Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.

ABSTRACT: Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials. However, improvement of their efficacy and selectivity for solid tumors is still required. Here, we describe a novel tandem T-cell recruiting trispecific antibody for the treatment of colorectal cancer (CRC). This construct, termed trispecific T-cell engager (TriTE), consists of a CD3-specific single-chain Fv (scFv) flanked by anti-epidermal growth factor receptor (EGFR) and anti-epithelial cell adhesion molecule (EpCAM) single-domain V_HH antibodies. The TriTE was well expressed in mammalian and yeast cells, bound the cognate anti

SUBMITTER: Tapia-Galisteo A 

PROVIDER: S-EPMC8837253 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature